Radius Health Inc (RDUS) Releases Earnings Results, Misses Expectations By $-0.19 EPS

Radius Health Inc (RDUS) reported quarterly earnings results on Thursday, May-5-2016. The company reported $-0.94 earnings per share for the quarter, missing the analyst consensus estimate by $-0.19. Analysts had a consensus of $-0.75. During the same quarter in the previous year, the company posted $-0.47 EPS.

Many Wall Street Analysts have commented on Radius Health Inc. Radius Health Inc was Initiated by Goldman to “Neutral” on Mar 30, 2016. Radius Health Inc was Downgraded by Jefferies to ” Hold” on Feb 24, 2016.

Radius Health Inc closed down -2.22 points or -6.30% at $33.04 with 6,42,929 shares getting traded on Wednesday. Post opening the session at $35, the shares hit an intraday low of $32.435 and an intraday high of $35.315 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

In a different news, on Jan 27, 2016, Lorraine A. Fitzpatrick (Chief Medical Officer) purchased 200 shares at $49.28 per share price. According to the SEC, on Nov 25, 2015, Robert Ward (President & CEO) sold 25,000 shares at $62.76 per share price. On Nov 13, 2015, Gary Hattersley (Chief Scientific Officer) sold 5,683 shares at $75.00 per share price, according to the Form-4 filing with the securities and exchange commission.

Radius Health Inc. is a science-driven biopharmaceutical company focused on developing therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases. The Company’s lead product candidate is abaloparatide (BA058) a bone anabolic for use in the reduction of fractures in postmenopausal osteoporosis delivered through subcutaneous injection which it refers to as abaloparatide-SC and is in Phase III development. The Company is leveraging its investment in Abaloparatide-SC to develop a line extension that is designed to improve patient convenience by enabling administration of abaloparatide through an investigational short-wear-time patch which the Company refers to as abaloparatide-TD. The Company’s clinical product portfolio also includes the investigational drug RAD1901 a selective estrogen receptor down regulator/degrader (SERD) and RAD140 a nonsteroidal selective androgen receptor modulator (SARM) for the treatment of breast cancer.

Radius Health Inc

Leave a Reply

Radius Health Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Radius Health Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.